Marinus Pharma (NASDAQ:MRNS)

CAPS Rating: 1 out of 5


How do you think MRNS will perform against the market?

Add Stock to CAPS Watchlist

All Players

26 Outperform
8 Underperform

All-Star Players

7 Outperform
6 Underperform

Wall Street

0 Outperform
0 Underperform

Top MRNS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

superstar2 (99.60)
Submitted September 23, 2016

Simply stated, it will go higher... my methodology is top secret however, so no explanations will be granted on this one.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


MRNS Summary

Recent Community Commentary

Read the most recent pitches from players about MRNS.


Member Avatar rhallbick (97.07) Submitted: 2/27/2018 2:11:40 PM : Underperform Start Price: $5.62 MRNS Score: +22.32

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The firm is developing ganaxolone, a small molecule, for the treatment of genetic orphan disorders, as well as other indications.

Ganaxalone had previously showed a statistically significant benefit as compared to a placebo in a Phase II study in the treatment of adults with focal onset seizures. However, ganaxalone failed to show a similar statistically significant benefit in a Phase III study for the same indication. Consequently, Marinus discontinued the program in adult focal onset seizures in 2016, and focused efforts for ganaxalone on postpartum depression, status epilepticus, and pediatric orphan indications. At least two Phase II trials are underway with results expected mid-late 2018.

There are other competing drugs under development for treating pediatric genetic epilepsies by Sage Therapeutics, GW Pharmaceuticals, Zogenix, Sunovion Pharmaceuticals, Zynerba, Alcobra, and Neuren Pharmaceuticals. Late 2017 saw some positive results from competitors in Phase III or late-stage studies.

Marinus Pharmaceuticals raised $37.7 million in net proceeds from a stock offering in Sept 2017, raising the number of outstanding shares to about 40.5 million. Their current cash burn rate is less than $20 million annually.

Since December 15, 2017, they have had 0 insider buys, and 2 insider sales for $10.05 million total.

Maintaining a CAPS downthumb if or when positive trial results are released would not be a good position, so relatively short-term pick.


Member Avatar Thartman0876 (53.91) Submitted: 2/26/2018 2:47:44 PM : Underperform Start Price: $5.36 MRNS Score: +18.34

Marinus Pharma's stock price was on a very hot streak for a while. Recently though it has been selling off, and I feel this will continue to be the trend for the next while. Due to the speculative nature of this stock I feel it will be volatile for a while until it reaches a lower valuation.


Member Avatar SaintCroix (98.93) Submitted: 1/24/2018 10:08:40 PM : Outperform Start Price: $8.00 MRNS Score: -42.77

A small-cap version of SAGE. MRNS has an anti-depression drug that is superior to Sage's. Both of these companies are likely acquisition targets. This company is way, way cheaper. Outperform.


Find the members with the highest scoring picks in MRNS.

Score Leader


mistermiranga (99.54) Score: +165.78

The Score Leader is the player with the highest score across all their picks in MRNS.

Member Name Member
Call Time
Score Commentary
portefeuille2 99.50 8/17/2016 Outperform 5Y $1.48 +191.89% +25.78% +166.11 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. mistermiranga 99.54 6/14/2016 Outperform 5Y $1.45 +197.93% +32.15% +165.78 0 Comment
RUNNER71 70.03 8/15/2016 Outperform 1Y $1.50 +188.00% +25.27% +162.73 0 Comment
gunda7907 31.73 6/13/2016 Outperform 5Y $1.50 +188.00% +31.05% +156.95 0 Comment
sdhwang422 71.69 7/7/2016 Outperform 5Y $1.55 +179.61% +31.33% +148.28 0 Comment
oscillation 81.20 6/13/2016 Outperform 5Y $1.57 +175.62% +31.13% +144.48 1 Comment
Momentum21 98.09 7/13/2016 Outperform 5Y $1.73 +149.71% +27.88% +121.83 0 Comment
orth5family < 20 9/29/2016 Outperform 5Y $1.86 +132.26% +26.71% +105.55 0 Comment
jack0071 72.63 7/18/2016 Outperform 5Y $2.07 +108.70% +26.96% +81.73 0 Comment
superstar2 99.60 9/23/2016 Outperform 5Y $2.19 +97.17% +26.85% +70.32 2 Comments

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MRNS.

Featured Broker Partners